23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
19:52 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

UCB's bimekizumab meets in Phase IIb for ankylosing spondylitis

UCB S.A. (Euronext:UCB) reported data from the Phase IIb BE AGILE trial in 303 patients with active ankylosing spondylitis showing that subcutaneous bimekizumab (UCB4940) every four weeks met the primary endpoint of a greater proportion...
21:04 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

UCB's bimekizumab meets in Phase IIb for psoriasis

UCB S.A. (Euronext:UCB) reported top-line data from the Phase IIb BE ABLE trial in 250 patients with moderate to severe chronic plaque psoriasis showing that subcutaneous bimekizumab (UCB4940) every 4 weeks met the primary endpoint...
21:17 , Jul 21, 2017 |  BC Extra  |  Clinical News

UCB psoriasis candidate headed for Phase III

UCB S.A. (Euronext:UCB) said bimekizumab (UCB4940) led to 90% clearance of plaque psoriasis per the Psoriasis Area and Severity Index (PASI 90) in up to 79% of patients in the Phase IIb BE ABLE study,...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

Bimekizumab: Phase Ib data

Top-line data from a double-blind, European Phase Ib trial in 52 patients with psoriatic arthritis who had inadequate responses to >=1 DMARD and/or 1 biologic showed that pooled data from the top 3 doses (n=30)...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Clinical News

UCB4940: Phase I started

UCB disclosed in its 2012 earnings that it began a Phase I trial of UCB4940. UCB Group (Euronext:UCB), Brussels, Belgium   Product: UCB4940   Business: Autoimmune   Molecular target: NA   Description: Undisclosed antibody-based product   Indication: Treat immunological...